Maryland is currently home to 2681 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of Children With Endocrine and Metabolic-Related Conditions
NCT02769975
Recruiting
Background: Endocrine glands give off hormones. Researchers want to learn more about the disorders that affect these glands in children. These disorders might be caused by changes in genes. Genes contain DNA, which is the blueprint of how a cell works. Researchers want to identify the genes involved in endocrine and metabolic disorders. This might help develop new ways to diagnose and treat the disorders. Objective: To study the inheritance of endocrine or metabolism disorders. Eligibility:... Read More
Gender:
ALL
Ages:
Between 3 months and 100 years
Trial Updated:
11/08/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Adrenal Insufficiency, Growth Disorder, Endocrine Diseases, Metabolic Disease, Bone Diseases, Metabolic
Register for Updates
Cannabidiol (CBD) in Adults With ASD
NCT05015439
Recruiting
There are no FDA approved treatments for use in adults with autism spectrum disorder (ASD), many of whom have distressing anxiety, mood disturbances, sleep problems, and agitation. Some researchers and individuals with ASD have noted that cannabidiol (CBD) is beneficial for those psychiatric problems. This study is to learn more about the effectiveness and safety of CBD in the treatment of psychiatric problems in adults with ASD. The study will last 14 weeks total, during which six weeks partici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2024
Locations: JHBMC, Baltimore, Maryland
Conditions: Autism Spectrum Disorder
Register for Updates
PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer
NCT06157151
Recruiting
This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: National Institute of Health, Bethesda, Maryland
Conditions: Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer
Register for Updates
The ACES Study for Aseptic Pleural Effusion
NCT06210685
Recruiting
The study will enroll recurrent aseptic pleural effusion patients who are designated by their physician as needing treatment to control the fluid. Baseline assessment will include a history and physical, chest imaging and quality of life questionnaires. After ACES implantation, patients will remain under hospital care for general observation as per standard-of-care before being discharged home with access to electronic diaries for tracking pain and dyspnea.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
11/05/2024
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Pleural Effusion
Register for Updates
Patient Specific Talus Spacer Post Approval Study
NCT05364606
Recruiting
Humanitarian Device Exemption Approved Patient Specific Talus Spacer Post Approval Study.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
11/05/2024
Locations: Mercy Institute for Foot & Ankle Reconstruction, Baltimore, Maryland
Conditions: Avascular Necrosis of the Talus
Register for Updates
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211
Recruiting
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the pr... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
A Safety and Effectiveness Prospective Blinded Clinical Study to Validate xBar System as Monitoring Tool for Anastomotic Leaks Detection
NCT06168669
Recruiting
Purpose: To validate the safety and effectiveness of xBar monitoring tool for detection of post-operative anastomotic leaks in subjects undergoing rectal/sigmoid resections with anastomosis. The clinical team is blinded to the leak detection of the xBar system.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
11/03/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Colorectal Surgery, Anastomotic Leak
Register for Updates
A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders
NCT06092346
Recruiting
Background: Pyrimidine and purine metabolism disorders (DPPMs) affect how the body metabolizes chemicals called pyrimidines and purines. DPPMs can cause dysfunctions throughout the body, especially in the brain, blood, kidneys, and immune system. People with DPPMs might have no symptoms, mild symptoms, or they may have severe, chronic symptoms, that can be fatal. DPPMs are not well understood, and researchers want to learn more about what causes them and how to treat them. Objective: To learn... Read More
Gender:
ALL
Ages:
Between 1 month and 100 years
Trial Updated:
11/02/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Purine-Pyrimidine Metabolism, Metabolic Disease, AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2, UNG, OMIM *191525, Hyper-IgM Syndrome 5, NT5C3A, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency, UMPS, OMIM *613891, Orotic Aciduria, DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis), DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency, DPYS, OMIM *613326, Dihydropyrimidinase Deficiency, UPB1, OMIM *606673, Beta-ureidopropionase Deficiency, CAD, *1140120, Developmental and Epileptic Encephalopathy, ADA2, OMIM *607575,Sneddon Syndrome; VAIHS, PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency, ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency, ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35, AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia, PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity, PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease, SLC22A12, OMIM *607096 Hypouricemia, SLC2A9, OMIM *606142 Hypouricemia, XDH, OMIM *607633, Xanthinuria Type 1, HPRT1, OMIM *308000 Lesch-Nyhan Disease, APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency, IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11, TPMT, OMIM *187680, Thoipurines, Poor Metabolism of, AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency, AK1, OMIM *103000, Adenylate Kinase Deficiency, AMPD3, OMIM*102772, AMP Deaminase Deficiency
Register for Updates
Multidisciplinary Approach to Reduce Cardiovascular Health Disparities
NCT06168968
Recruiting
The goal of this observational study is to investigate the potential differences in thrombogenicity between black and white patients admitted with atherothrombotic events including acute coronary syndrome, multi-vessel coronary disease, and ischemic stroke. Participants will engage in laboratory testing and health outcome assessments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland
Conditions: Acute Coronary Syndrome, Multi Vessel Coronary Artery Disease, Ischemic Stroke
Register for Updates
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443
Recruiting
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Johns Hopkins University Medical Center - 1627, Baltimore, Maryland
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use
NCT05521880
Recruiting
Standard of care for patients with opioid use disorder and complicated infections is discharge to subacute nursing facilities on IV antibiotics until completion of treatment course. We aim to determine the efficacy of an alternative strategy using intermittent outpatient oritavancin therapy dosed weekly combined with initiation and continuation of medication assisted treatment for opioid use disorder for completion of antimicrobial therapy in a 12 week prospective, open-label study. Patients hos... Read More
Gender:
ALL
Ages:
Between 18 years and 88 years
Trial Updated:
11/01/2024
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Substance Use Disorders, Infection, Soft Tissue, Bacteremia, Osteomyelitis Acute, Septic Arthritis
Register for Updates
4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration
NCT05197270
Recruiting
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment
Gender:
ALL
Ages:
50 years and above
Trial Updated:
11/01/2024
Locations: Cumberland Valley Retina Consultants, Hagerstown, Maryland
Conditions: Neovascular (Wet) Age-Related Macular Degeneration
Register for Updates